Friday, November 01, 2013

IRETA Developes Guidelines for the Management of Benzodiazepines in MAT

November 1, 2013

EXECUTIVE SUMMARY

In  2012,  under  contract  with  the  Philadelphia  Department  of  Behavioral  Health  and  Intellectual disAbility Services (DBHIDS), and with additional support from Community Care Behavioral Health Organization  (Community  Care),  the  Institute  for  Research,  Education  and  Training  in  Addictions (IRETA)  conducted  a  project  to  determine  best  practice  guidelines  for  the  management  of  benzodiazepines in medication-assisted treatment (MAT). The project was conceived in response to frequent  benzodiazepine  use  among  individuals  in  MAT  and  a  relative  absence  of  research -based guidance  on  clinically  effective  treatment  strategies  for  managing  their  use.  Designed  to  be  a resource for clinicians, these guidelines aim to distinguish areas of scientific/clinical consensus and areas where that does not exist.   They are not intended to dictate clinical practice.

This  report  details  the  development  of  the  project,  methods,  results  and  the  final  list  of  practice guidelines.  IRETA  utilized  the  RAND/UCLA  Appropriateness  Method  to  determine  appropriate guideline statements based on the research and clinical experience of a panel of experts in the field. The two-round rating process and half-day expert panel meeting yielded 225 guideline statements, which IRETA  distilled into  a  shorter list of guidelines for practitioners to  use in real-world clinical settings.

Recommendations from the expert panel members include:
  • CNS depressant use is not an absolute contraindication for the use of either methadone or buprenorphine in MAT, but is a reason for caution because of potential respiratory depression. Serious overdose and death may occur if MAT is administered in conjunction with benzodiazepines, sedatives, tranquilizers, antidepressants, or alcohol.

  • Individuals who use benzodiazepines, even if used as a part of long-term therapy, should be considered at risk for adverse drug reactions including overdose and death.

  • Many people presenting to services have an extensive history of multiple substance dependence and all substance abuse, including benzodiazepines, should be actively addressed in treatment.

  • MAT should not generally be discontinued for persistent benzodiazepine abuse, but requires the implementation of risk management strategies.

  • Clinicians should ensure that every step of decision-making is clearly documented.

During  the  half-day  meeting  in  September  2012,  expert  panelists  added  an  additional  guideline statement:  “Clinicians  would  benefit  from  the  development  of  a  toolkit  about  the  management  of benzodiazepines in methadone treatment that includes videos and written materials for individuals in  MAT.”   This  recommendation  is  consistent  with  the  overarching  theme  of  patient  education, which was discussed lengthily at the project’s Kickoff Conference in February 2012 and emerged as a significant issue in the final practice guidelines.

Download: Management of Benzodiazepines in MAT

Resource:  IRETA
 

Tuesday, October 22, 2013

Reckitt Benckiser may sell pharmaceuticals business


By Martinne Geller


LONDON (Reuters) - Reckitt Benckiser may sell its pharmaceuticals unit, which has been suffering from declining sales of its main heroin addiction drug, to focus on growing consumer health and household cleaning products businesses.

The British consumer goods group said on Tuesday it was reviewing options for the pharmaceuticals business, which analysts said could fetch over 2 billion pounds ($3.2 billion) and appeal to international drugmakers.
Download:
http://www.methadone.org/downloads/documents/2013 1023Reuters Reckitt Benckiser may sell pharmaceuticals business.pdf

Tuesday, October 01, 2013

The Benefits of Including Methadone Treatment in Illinois’ State Medicaid Plan

The Illinois Association for Medication Assisted Addiction Treatment
October 2013

Executive Summary

Methadone is an inexpensive medication approved by the U.S. Food and Drug Administration for the treatment of heroin and other opioid dependence. Studies indicate that methadone reduces relapse, emergency department visits and hospital admissions. In general, the stability methadone provides helps patients better manage their overall health.

Including methadone treatment in Illinois’ State Medicaid Plan will reduce healthcare costs and help the state address the growing epidemic of opioid dependence. Patients can only access methadone treatment for their opioid dependence through the highly regulated Opioid Treatment Program (OTP) system. The system requires programs be registered with the Drug Enforcement Administration, certified by the federal Health and Human Services’ Center for Substance Abuse Treatment and licensed by the Illinois Department of Human Services’ Division of Alcoholism and Substance Abuse.

OTPs utilize a multidisciplinary team comprised of physicians, nurses, and counselors to address the bio-psycho-social needs of each individual patient. This holistic approach to treatment has been in place in OTPs for more than 40 years, long before most other systems embraced the health home model. The strong positive relationships between patients and professionals in OTPs helps patients feel empowered to address their own health needs.

Numerous studies have documented the cost savings generated by stabilizing opioid dependent individuals on methadone and helping them manage their comorbid conditions. Emergency department visits and hospital admissions are significantly reduced because patient health is carefully monitored and addressed. In spite of medical evidence documenting the effectiveness of methadone treatment and the cost savings achieved, some health plans have excluded this treatment modality. Patient advocates have suggested this is largely due to the stigma related to heroin addiction.

Untreated opioid dependence in Illinois leads to unnecessary emergency department visits and hospital admissions. Some of these visits are due to drug overdoses or attempts to seek treatment for withdrawal symptoms. However, others are due to the multiple unmanaged comorbid conditions, such as diabetes and hypertension, which are highly prevalent in opioid dependent individuals.

Illinois’ administrative leadership has demonstrated its commitment to resolving Illinois’ fiscal crisis. The cost savings achieved by covering methadone treatment in Illinois’ State Medicaid Plan can be part of this solution. In addition to saving taxpayer dollars in unnecessary hospitalizations, providing increased access to treatment aligns with three core objectives of Illinois’ Budgeting for Results initiative: 1) to improve the overall health of Illinois residents; 2) to meet the needs /improve the quality of life for the most vulnerable persons; and 3) to increase individual and family self-sufficiency.

Download

Thursday, September 26, 2013

Report on the Save Medicaid Access and Resources Together (SMART) Act

From the Illinois Departments of Healthcare and Family Services
and Human Services, Division of Alcohol and Substance Abuse

September 27, 2013

Report on the Detoxification Services Planning Process and Resulting Recommendations as per the Save Medicaid Access and Resources Together (SMART) Act

Senate Bill 2840- Public Law 97- 0689


The Save Medicaid Access and Resources Together (SMART) Act (P.A. 97-689) made two changes in the Illinois Medicaid Program for our clients with substance use disorders who are admitted to hospitals for in-patient detoxification services.

First, the new law placed limitations and required concurrent review for every hospital detoxification stay within 60 days of a previous detoxification stay. Second, it required the Department of Healthcare and Family Services (HFS), along with our sister agency, the Division of Alcoholism and Substance Abuse (DASA) of the Department of Human Services (DHS), to “convene a workgroup to develop recommendations for quality standards, diversion to other settings, and admission criteria for patients who need inpatient detoxification”. Pursuant to P.A. 98-104 and stakeholder involvement, these recommendations are being published.

We understood from the outset that restrictions on hospital admissions and readmissions would not alone achieve the State’s goal: to facilitate access to medically appropriate detoxification services, in the most appropriate setting, with appropriate linkages to community based substance abuse treatment and recovery support services. That is why we are working with providers and managed care entities to build integrated delivery systems around these clients, which will offer a network of health, behavioral health and social services, with assistance from a care coordinator to help navigate the system. In the short term, we will test the effectiveness of these linkages through a demonstration program which partners hospitals and community-based providers.

This report is the product of a deliberative process that included representatives from hospitals, community-based providers, managed care entities and state agencies. We invite your feedback and comments, as we set about to implement these new policies. We are convinced that the implementation of new policies, programs and protocols with greater access to medication assisted treatment, and a cohesive and coordinated approach to care will improve health outcomes for these clients with behavioral health needs.

 Download

Tuesday, March 19, 2013

SMART Act Implementation Status Report

Illinois Department of Healthcare and Family Services
March 19, 2013

Senate Appropriation Committee Hearing

(Spreadsheet)
 
Download

Friday, December 28, 2012

Some MaineCare Patients will still have Access to Methadone

Portland Press Herald
By WANDA CURTIS Kennebec Journal Correspondent

A task force developed criteria for continued MaineCare coverage of certain drug treatments.

Health officials say Mainers who need certain drugs to treat addiction won't be cut off entirely, despite legislation to cut off treatment for some.

MaineCare coverage for treatment with methadone and Suboxone is due to end Tuesday for those who have been covered for at least 24 months. A bill passed by the Legislature established the 24-month lifetime limit.

But a task force of medical providers, substance abuse treatment providers, government officials and patient advocates has developed criteria for continued MaineCare coverage of medically necessary methadone and Suboxone treatments.

That may avert what was predicted to become an unprecedented drug withdrawal crisis in January. Methadone and Suboxone are used to treat opiate addiction.

The medical director of MaineCare services, Kevin Flanigan, said the task force developed guidelines for continued coverage for people who need the treatment. He said Suboxone funding will end Jan. 1 for people who have reached the two-year limit -- the 24 months don't need to be consecutive -- only if medical providers are unable to get authorization to continue the treatment before the deadline.

Flanigan said the task force has identified specific behavior that may help indicate whether Suboxone treatment has been successful. He said people reviewing authorization applications will ask questions about clients such as:

  • Have they been able to reunite with their families?
  • Have they been able to return to work?
  • Have they been able to engage in social or community or recreational activities again?
  • Is there a spiritual component to their life that was absent before?
  • Are they no longer having difficulties with the legal system?
  • Are they in constructive activities their provider has asked them to participate in?


Flanigan said providers will also be asked whether a client is receiving the lowest optimal dose, in determining whether Suboxone treatment has been effective for them.

He said that if the provider says the person relapsed every time weaning was attempted, then treatment hasn't been successful and the provider should discuss other options.

Flanigan said that if Suboxone treatment has been deemed successful and it's determined to be medically necessary, coverage for the treatment will be approved for six-month increments, and the provider will be required to reapply every six months.

Flanigan said that if a client is denied, the provider can reapply after the client is given another opportunity to meet the criteria.

Flanigan said no one would be required to discontinue Suboxone treatment cold turkey if MaineCare funding is denied. He said the patient would be allowed a three-month tapering period during which treatment would still be funded.

Flanigan said people who will reach the 24-month coverage limit in January should contact their medical providers immediately to determine whether the provider applied for authorization or whether the client must seek another payment source.

For methadone coverage, Flanigan said the two-year countdown begins Jan. 1.

Unlike the new rules for Suboxone treatment, it's not retroactive.

He said that count starts "whether it's their first day of treatment or the first day of their ninth year of treatment."

Both of those funding decreases, which are part of state budget cuts, come at a time when Maine reports the highest per capita rate of people seeking treatment for opiate addiction in the country.

Roy Miller, a physician who practices at Sheepscot Valley Health Center in Coopers Mills, said providers are re-examining their prescribing practices because they've been warned that narcotics have been overprescribed in the past.

"We're cutting back," he said.

Miller said the limit was established because of financial constraints, not because two years was proven to be the optimal time to discontinue treatment.

He said some addiction specialists suggest teenagers who get addicted to certain drugs may need lifelong treatment because the drugs affect their brains.

Miller said the time needed for treatment to be effective varies from client to client.

Miller said Suboxone is expensive -- $7 to $8 per pill -- but it allows people with opiate addiction to live more normal lives because they don't have to travel to a methadone clinic daily for treatment.

A generic medication costs less but doesn't produce the same results, he said.

Miller said Suboxone has been effective with patients he's treated over the last four years.

"After they've received treatment, many of them are able to hold jobs and get their families back together," he said.

Sunday, May 27, 2012

Clinicians Say Giving Addicts Maintenance Methadone Serves Them and Society Best

By Christopher Williams, Sun Journal
Bangor Daily News May 27, 2012

When Zachary Tomaselli was sent to prison for sex crimes last month, he asked the judge to delay his sentence for a week.
The Lewiston man said he needed those seven days to wean himself off methadone, the drug he had been getting at a clinic to help him kick a prescription drug habit.
Thousands of addicts living “on the outside” visit Maine’s for-profit clinics for weeks, months and even years for their prescribed methadone doses. A large majority of those addicts are MaineCare clients, paying for methadone treatments with taxpayer dollars.
According to the Department of Health and Human Services, Maine spends about $9 million in state and federal funds every year to dose just over 3,100 MaineCare and Medicare clients every day. The state spends another $7 million a year to transport clients to methadone clinics.
That’s $5,140 per MaineCare patient per year.
Under the recently passed state budget, MaineCare clients are subject to a 24-month lifetime cap for methadone treatment. That cap is expected to save Maine more than $1.3 million a year.
According to Susan Sullivan, director of CAP Quality Care Clinic in Westbrook, patients there “are anxious and afraid of losing their treatment. Some are looking to be proactive and starting to taper themselves out because they don’t know what’s going to happen.”
If Tomaselli believed he could lick his drug habit in just a week, why wouldn’t — or shouldn’t — every drug addict do the same?
The answer, according to experts, is as complex as the subject of drug addiction itself.
Withdrawal is harsh reality
The good news for Tomaselli, experts say, is that he likely wasn’t in any danger of serious health risks had he decided to go cold turkey before trading his street clothes for jail garb.
The bad news — depending on how long he had been treated with methadone and at what dosage — is that his withdrawal might have been more grueling than his looming 3½-year prison sentence.
Dr. Michael E. Kelley, chief of psychiatry at St. Mary’s Regional Medical Center in Lewiston, said the effects of withdrawal from methadone are unique.
Because the medication is used as a maintenance narcotic for clients limited to a single dose each day, the drug typically stays in the body longer than other narcotics, he said.
“It is incredibly long-lasting,” he said.
That means withdrawal from that drug can linger for a week or longer. Sometimes up to a month.
Although not physically dangerous in an otherwise healthy adult, withdrawal can make you feel like you’re dying, Kelley said in an interview at the hospital, where he works as an addiction specialist, treating people with chemical dependency in residential and day programs.
“They can have a very miserable withdrawal,” he said.
It often includes severe flulike symptoms, including vomiting, diarrhea, sweating, chills and muscle cramps.
“But you won’t die,” Kelley said. The only possible medical risk is dehydration, he said.
The greater risk for narcotic addicts is relapse, experts say.
‘Jail isn’t a hospital’
While withdrawal from narcotics, including methadone, is usually safe, withdrawal from certain other drugs and alcohol can be dangerous, even fatal, according to medical experts.
Withdrawal from alcohol, benzodiazepines (tranquilizers) and barbiturates can be “very dangerous,” Kelley said.
Stopping those drugs too quickly can sometimes trigger seizures, heart arrhythmias and delirium tremens (in alcoholics), he said. The latter can be dangerous because those patients become disoriented and may inadvertently harm themselves.
Jails sometimes bring prisoners into the emergency room if they’re suspected of alcoholism or addiction to tranquilizers and show signs of withdrawal, Kelley said.
While the jail might let someone addicted to narcotics “tough it out,” they won’t take a chance on the other addictive populations, Kelley said.
“The jail’s not going to risk that,” he said. “The jail isn’t a hospital.”
When inmates come to St. Mary’s emergency department for medical clearance, hospital staff screens patients for drugs and toxic substances, checking their general health.
Doctors quiz the patients about drug use.
“Hopefully, they’ll be honest.” he said. But, too often they’re not. They fear their candor might get back to their probation officers. Although emergency room chats with doctors are confidential, inmates are on their guard generally and may not confide in the medical staff.
“Sometimes they lie to us,” Kelley said, “which is part of the scary thing.”
Doctors typically watch inmates suspected of drug or alcohol abuse for 12-16 hours, he said, but added, “There is no magic [time] line.” And there is no predicting a patient’s tolerance based on his or her history of drug or alcohol use.
No methadone for prisoners
At Maine’s correctional facilities, including its prisons, the state contracts its medical services with Corizon, a national company based in Tennessee. Three county jails in Maine, including Androscoggin County Jail in Auburn, also have contracts with Corizon.
The company has 150 health care professionals working at the state facilities. An additional 65 workers staff the three jails, according to Pat Nolan, a company spokesman.
Corizon would provide only written answers to questions posed by the Sun Journal for this story.
While it declined to detail how chemically dependent inmates are treated during intake at Maine’s prisons and jails, the company said it uses “standard, humane and medically approved detox protocols for these addictions.”
Inmates who attend methadone clinics prior to incarceration are not dispensed methadone at any of the correctional facilities where Corizon is under contract. Pregnant inmates using methadone are treated by an off-site OB-GYN doctor licensed in prescribing Buprenorphine, a semisynthetic opioid used to treat opiate-based drug addiction. After delivery, those inmates follow the standard detox protocols, Nolan said.
If an inmate were to come to jail or prison with a current prescription for Oxycontin or oxycodone, those drugs wouldn’t be dispensed, except in “very rare” cases, the company said.
Inmates with a medical marijuana certificate won’t be dispensed that drug at Maine’s prisons and jails, either, but substitutions could be considered on a case-by-case basis, the company said.
In all, roughly 90 percent of the inmates who enter Maine’s prisons and other correctional facilities have a history of addiction to one or more drugs (including narcotics, benzodiazepines or barbiturates) or alcohol.
Relapse rate is high
So, why don’t all methadone addicts spend a week weaning themselves from the drug like Tomaselli?
Some may try. But most will need more time. And a small percentage likely will need to stay on methadone until they die, experts say.
Sullivan, the director at CAP, where opioid addicts are treated with methadone, said the first goal is to stabilize clients on a suitable dose of medication.
Opioid addiction is a brain disease, she said, best treated with medication and psychosocial support. Clients who come to her clinic get both.
Like any addiction, “It’s a progressive disease,” she said. “The longer you use, the worse it gets and the more you use … so that treatment is based on the individual.”
Studies have found that patients with this chronic disease undergo a change in brain chemistry in which they are lacking free endorphins which, for many, means they likely will need medication throughout their lifetimes, she said.
The long-term goal of treatment is to improve a client’s ability to function at home, at a job and in the world.
Studies show it works.
Typically, relapse rates are 70-90 percent among those who leave methadone maintenance treatment, she said, even among those who taper to zero.
An alternative for opioid addicts to being on a maintenance program at a methadone clinic may be to seek street drugs, which can expose addicts to hepatitis C and HIV through shared and dirty needles, blood clots and possible overdose, among other health risks.
Some may try prescription shopping, a ploy medical professionals are increasingly more aware of and on which federal and state drug agencies have cracked down.
A patient on Sullivan’s caseload was in methadone treatment before he tapered his dosage to zero and left, she said.
“Within a year, he relapsed,” she said. “And then he came to this clinic and he’s been here about 9½ years and he’s tapering out, decreasing his medication so he can leave. To zero eventually. That’s his desire.”
By taking a gradual approach, that client is more likely to succeed, she said.
She said patients and staff at CAP are anxious about the new 24-month MaineCare cap. Under the new DHHS rule, that cap can be exceeded with prior MaineCare authorization.
However, Sullivan said, “We’re waiting for the criteria for prior authorization. We have no idea what that’s going to be.” Once that process is established, “that will probably be the determinant on who loses treatment,” she said.
In the 10 years her clinic has been open, Sullivan said the number of clients has averaged about 550 at any given time.
“We’ve had over 3,000 patients come and go,” she said. “And some stay.”
The MaineCare cap will have an adverse effect on methadone clinics across the state, Sullivan said. Nearly 70 percent of all clients are on MaineCare. And, under the MaineCare reimbursement cap, that patient load is likely to decrease if MaineCare-capped patients can’t pay out-of-pocket.
Fewer than 200 methadone patients pay for treatments with private insurance, which leaves about 1,000 patients without MaineCare or private insurance paying for their own treatments.
Although her clinic exists to treat addiction to narcotics, some people who became addicted started with a doctor’s prescription for pain, she said.
Pain and narcotic addiction “are not necessarily mutually exclusive,” she said.
“Even addicts get real pain,” St. Mary’s Dr. Kelley said. Those are the ones who are likely to stay on methadone or Suboxone (a partial narcotic, offered by St. Mary’s instead of methadone) the rest of their lives, he said.
The other group that would have to stay on clinical treatment includes those who are so addicted they likely would harm themselves otherwise through risky drug behavior. No rehab program, however proven and long-term, is going to work for them.
“There’s just that once-in-a-while person that everything’s failed, no matter what,” he said.
But studies he’s seen show that opioid addicts who attend methadone clinics are less likely to contract HIV or hepatitis C and less likely to be charged with crimes. They work more days and achieve higher levels of education.
“So it does reduce the harm, not only to them, but to society, in many ways [to maintain methadone treatments],” he said.
St. Mary’s approach to addiction is that 99.9 percent of addicts can be weaned off and can stay off drugs and alcohol — “all chemicals,” Kelley said.
“And that requires a hell of a lot more than just taking a pill,” he said. “It requires learning about yourself, doing what we call the recovery work … learning why I use, how I can cope with life without drugs.”
Addicts who have been using drugs to cope with life will have to relearn how to cope without them. “That’s how they dealt with every single emotion,” he said.
And some addicts who have been abusing drugs since their early teens will have to learn those coping skills for the first time.
“How many coping skills do you have at 13 years old?” Kelley said. “Once you start using drugs for everything, you don’t learn new coping skills because you don’t need to. You’ve got a coping skill. It’s right there in your pocket. And so, some of these people are starting from scratch.”

Link to Poll